Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 13/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 13/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.60 |
| ▸ | MAPT | P10636 | 12/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.55 |
| ▸ | LMNA | P02545 | 5/20 | 0.55 |
| ▸ | HTT | P42858 | 3/20 | 0.55 |
| ▸ | PKM | P14618 | 3/20 | 0.55 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | CRHBP | P24387 | 1/20 | 0.54 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CTSB | P07858 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11973643 | 0.85 | MEN1 (0.63) | MEN1KMT2AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL11972798 | 0.82 | MAPT (0.62) | MEN1KMT2AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL14573268 | 0.82 | MEN1 (0.60) | MEN1KMT2AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL10945384 | 0.82 | G6PD (0.60) | MEN1KMT2AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL8112457 | 0.79 | MEN1 (0.68) | MEN1KMT2AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL6537483 | 0.79 | ALDH1A1 (0.59) | MEN1KMT2AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL10040153 | 0.79 | MAPT (0.65) | MEN1KMT2AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL11973580 | 0.78 | MEN1 (0.77) | MEN1KMT2AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL27462655 | 0.78 | MEN1 (0.66) | MEN1KMT2AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL1682758 | 0.77 | MAPT (0.69) | MEN1KMT2AALDH1A1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103492028-B | Sulfonaminoquinoline hepcidin antagonists | 维福（国际）股份公司 | 2017-02-08 | — | — | CN | disclosed |
| EP-2675526-B1 | NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS | VIFOR (INTERNATIONAL) AG (CH) | 2017-02-01 | — | — | EP | disclosed |
| US-9102688-B2 | Sulfonaminoquinoline hepcidin antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2015-08-11 | — | — | US | disclosed |
| US-20140364424-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2014-12-11 | — | — | US | disclosed |
| US-20120214803-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214803-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | HAMP, SLC40A1, FTH1 | MEN1 2680/4885KMT2A 3298/4885ALDH1A1 3570/4885 |
| US-20140364424-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | HAMP, SLC40A1, FTH1 | MEN1 2680/4885KMT2A 3298/4885ALDH1A1 3570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.